Kusumanto YH - Search Results

1

Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer.

van der Wall E, Richel DJ, Kusumanto YH, Rutgers EJ, Schornagel JH, Schaake-Koning CC, Peterse JL, Rodenhuis S. van der Wall E, et al. Among authors: kusumanto yh. Ann Oncol. 1993 Nov;4(9):791-2. doi: 10.1093/oxfordjournals.annonc.a058667. Ann Oncol. 1993. PMID: 8280661 Free article.

2

Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters.

Oldenborg S, Griesdoorn V, van Os R, Kusumanto YH, Oei BS, Venselaar JL, Zum Vörde Sive Vörding PJ, Heymans MW, Kolff MW, Rasch CR, Crezee H, van Tienhoven G. Oldenborg S, et al. Among authors: kusumanto yh. Radiother Oncol. 2015 Nov;117(2):223-8. doi: 10.1016/j.radonc.2015.10.017. Epub 2015 Nov 2. Radiother Oncol. 2015. PMID: 26542015

3

Reirradiation + hyperthermia for recurrent breast cancer en cuirasse.

Oldenborg S, Rasch CRN, van Os R, Kusumanto YH, Oei BS, Venselaar JL, Heymans MW, Zum Vörde Sive Vörding PJ, Crezee H, van Tienhoven G. Oldenborg S, et al. Among authors: kusumanto yh. Strahlenther Onkol. 2018 Mar;194(3):206-214. doi: 10.1007/s00066-017-1241-7. Epub 2017 Dec 20. Strahlenther Onkol. 2018. PMID: 29264624 Free PMC article.

4

Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor.

Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Kusumanto YH, et al. Angiogenesis. 2003;6(4):283-7. doi: 10.1023/B:AGEN.0000029415.62384.ba. Angiogenesis. 2003. PMID: 15166496

5

Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound.

Kusumanto YH, Mulder NH, Dam WA, Losen M, De Baets MH, Meijer C, Hospers GA. Kusumanto YH, et al. Drug Deliv. 2007 Jul;14(5):273-7. doi: 10.1080/10717540601098807. Drug Deliv. 2007. PMID: 17613014

6

Circulating vascular endothelial growth factor (VEGF) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia.

Kusumanto YH, Meijer C, Dam W, Mulder NH, Hospers GA. Kusumanto YH, et al. Drug Target Insights. 2007;2:105-9. Epub 2007 May 18. Drug Target Insights. 2007. PMID: 21901067 Free PMC article.

7

Systemic VEGF levels after coronary artery bypass graft surgery reflects the extent of inflammatory response.

Kusumanto YH, Tio RA, Loef BG, Sluiter WJ, Mulder NH, Hospers GA. Kusumanto YH, et al. Acute Card Care. 2006;8(1):41-5. doi: 10.1080/14628840500480449. Acute Card Care. 2006. PMID: 16720427

8

Circulating vascular endothelial growth factor during the normal menstrual cycle.

Kusumanto YH, Hospers GA, Sluiter WJ, Dam WA, Meijer C, Mulder NH. Kusumanto YH, et al. Anticancer Res. 2004 Nov-Dec;24(6):4237-41. Anticancer Res. 2004. PMID: 15736478 Free article.

9

Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.

Kusumanto YH, Hospers GA, Mulder NH, Tio RA. Kusumanto YH, et al. Int J Cardiovasc Intervent. 2003;5(1):27-34. doi: 10.1080/14628840304612. Int J Cardiovasc Intervent. 2003. PMID: 12623562 Review.

10

Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product.

de Leeuw K, Kusumanto Y, Smit AJ, Oomen P, van der Hoeven JH, Mulder NH, Hospers GA. de Leeuw K, et al. Diabet Med. 2008 Oct;25(10):1241-4. doi: 10.1111/j.1464-5491.2008.02557.x. Diabet Med. 2008. PMID: 19046206

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page